RCAG
JSPR icon

Rehmann Capital Advisory Group’s Jasper Therapeutics JSPR Stock Holding History

Rehmann Capital Advisory Group’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.4K Buy
+15,300
New +$21.2K ﹤0.01% 676

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Rehmann Capital Advisory Group's JSPR Position: Q1 2026 in Review

Rehmann Capital Advisory Group opened a new position in Jasper Therapeutics (JSPR) in Q1 2026: 15,300 shares worth $13.4K. The stake represents ﹤0.01% of the portfolio and ranks #676 among its holdings.

58 funds tracked by Wall St. Rank hold JSPR as of Q1 2026.

  • Rehmann Capital Advisory Group held 15,300 shares of Jasper Therapeutics worth $13.4K as of Q1 2026.
  • Jasper Therapeutics was a new Rehmann Capital Advisory Group position in Q1 2026.
  • Jasper Therapeutics made up ﹤0.01% of Rehmann Capital Advisory Group's portfolio in Q1 2026, its #676 holding.
  • 58 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2026.

Based on Rehmann Capital Advisory Group's 13F filing for Q1 2026, filed 15 May 2026.